A phase I/II study of NB1011 administered intravenously by continuous infusion in an every second week regimen with open-label continuation in cancers that overexpress the enzyme thymidylate synthase
Phase of Trial: Phase I/II
Latest Information Update: 26 Sep 2012
At a glance
- Drugs NB 1011 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Kiadis
- 24 Jan 2008 Status change from recruiting to completed, from clinicaltrials.gov record.
- 24 Jan 2006 New trial record.